Palvella Therapeutics (NASDAQ:PVLA) Trading Up 5.6% – Time to Buy?

Shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA) were up 5.6% on Wednesday . The company traded as high as $113.49 and last traded at $110.55. Approximately 16,636 shares changed hands during mid-day trading, a decline of 94% from the average daily volume of 272,438 shares. The stock had previously closed at $104.67.

Analyst Upgrades and Downgrades

Several research firms recently commented on PVLA. Mizuho boosted their price objective on shares of Palvella Therapeutics from $205.00 to $250.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 25th. BTIG Research upped their price target on shares of Palvella Therapeutics from $192.00 to $215.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. HC Wainwright increased their price target on shares of Palvella Therapeutics from $255.00 to $270.00 and gave the company a “buy” rating in a research report on Tuesday, March 24th. Chardan Capital restated a “buy” rating and set a $240.00 price objective on shares of Palvella Therapeutics in a research report on Thursday, May 21st. Finally, Wall Street Zen lowered Palvella Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Palvella Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $199.53.

Palvella Therapeutics Trading Up 5.8%

The stock has a market capitalization of $1.59 billion, a price-to-earnings ratio of -26.55 and a beta of -0.14. The business has a 50 day simple moving average of $121.15 and a 200-day simple moving average of $107.27.

Palvella Therapeutics (NASDAQ:PVLA) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($1.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.30). Research analysts predict that Palvella Therapeutics, Inc. will post -5.26 EPS for the current year.

Insider Buying and Selling

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of the stock in a transaction that occurred on Wednesday, March 18th. The shares were sold at an average price of $117.99, for a total transaction of $507,592.98. The transaction was disclosed in a filing with the SEC, which is available at this link. Company insiders own 20.50% of the company’s stock.

Institutional Trading of Palvella Therapeutics

Institutional investors have recently made changes to their positions in the stock. Avidity Partners Management LP raised its position in shares of Palvella Therapeutics by 262.7% in the 1st quarter. Avidity Partners Management LP now owns 70,000 shares of the company’s stock worth $8,726,000 after buying an additional 50,700 shares during the period. Arete Wealth Advisors LLC purchased a new stake in Palvella Therapeutics during the first quarter valued at about $2,178,000. Bank of America Corp DE grew its position in Palvella Therapeutics by 25.4% during the first quarter. Bank of America Corp DE now owns 37,972 shares of the company’s stock valued at $4,733,000 after acquiring an additional 7,700 shares during the period. The Manufacturers Life Insurance Company increased its stake in Palvella Therapeutics by 688.9% during the first quarter. The Manufacturers Life Insurance Company now owns 17,907 shares of the company’s stock worth $2,232,000 after acquiring an additional 15,637 shares during the last quarter. Finally, First Light Asset Management LLC raised its holdings in shares of Palvella Therapeutics by 38.3% in the 1st quarter. First Light Asset Management LLC now owns 980,758 shares of the company’s stock worth $122,251,000 after purchasing an additional 271,617 shares during the period. 40.11% of the stock is owned by hedge funds and other institutional investors.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.